Sugi Predict

Sugi Predict / Compounds / SCHEMBL1900249

SCHEMBL1900249

SCHEMBL1900249

Cc1nc(Br)sc1C(=O)Cl

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.44
▸ HPGD P15428 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ CNR1 P21554 2/20 0.36
▸ MAPT P10636 3/20 0.35
▸ SMN1; SMN2 Q16637 4/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ GAA P10253 3/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CNR2 P34972 1/20 0.33
▸ PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18482858 0.83 ALDH1A1 (0.40) ALDH1A1HPGDTSHRL3MBTL1CNR1
SCHEMBL289401 0.80 RXFP1 (0.49) ALDH1A1HPGDTSHRL3MBTL1MAPT
SCHEMBL241856 0.80 ALDH1A1 (0.61) ALDH1A1HPGDTSHRSMN1; SMN2RAB9A
SCHEMBL3344131 0.80 CNR1 (0.47) ALDH1A1HPGDTSHRL3MBTL1CNR1
SCHEMBL3500221 0.78 ALDH1A1 (0.70) ALDH1A1HPGDTSHRL3MBTL1MAPT
SCHEMBL2267607 0.78 ALDH1A1 (0.44) ALDH1A1HPGDTSHRL3MBTL1CNR1
SCHEMBL299157 0.78 LMNA (0.45) ALDH1A1HPGDTSHRL3MBTL1MAPT
SCHEMBL18168614 0.78 ALDH1A1 (0.44) ALDH1A1HPGDTSHRL3MBTL1CNR1
SCHEMBL18452971 0.78 GSK3B (0.44) ALDH1A1HPGDTSHRL3MBTL1MAPT
SCHEMBL27564565 0.77 ALDH1A1 (0.67) ALDH1A1HPGDTSHRL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807976-B2 Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
EP-2496230-B1 IRE-1 ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH INC (CN) 2020-02-26 — — EP disclosed
EP-2496230-B1 IRE-1 ALPHA INHIBITORS FOSUN ORINOVE PHARMATECH INC (CN) 2020-02-26 — — EP disclosed
US-10407419-B2 Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2019-09-10 — — US disclosed
US-20180118732-A1 QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2018-05-03 — — US disclosed
US-20180072745-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-03-15 — — US disclosed
US-20180072745-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-03-15 — — US disclosed
US-9856266-B2 IRE-1alpha inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-02 — — US disclosed
US-9856266-B2 IRE-1alpha inhibitors SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD. (CN) 2018-01-02 — — US disclosed
US-20170166576-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-06-15 — — US disclosed
US-9493435-B2 IRE-1α inhibitors MANNKING CORPORATION (US) 2016-11-15 — — US disclosed
US-9493435-B2 IRE-1α inhibitors MANNKING CORPORATION (US) 2016-11-15 — — US disclosed
WO-2016171756-A1 QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. (US) 2016-10-27 — — WO disclosed
US-20160311818-A1 QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-10-27 — — US disclosed
US-20120270877-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2012-10-25 — — US disclosed
US-20120270877-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2012-10-25 — — US disclosed
US-20120270877-A1 IRE-1alpha INHIBITORS MANNKIND CORPORATION (US) 2012-10-25 — — US disclosed
EP-2496230-A1 IRE-1 ALPHA INHIBITORS MannKind Corporation (US) 2012-09-12 — — EP disclosed
WO-2011056744-A1 IRE-1 α INHIBITORS MANNKIND CORPORATION (US) 2011-05-12 — — WO disclosed
WO-2011056744-A1 IRE-1 α INHIBITORS MANNKIND CORPORATION (US) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407419-B2 Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 ALDH1A1 594/4885HPGD 122/4885TSHR 3244/4885
US-20160311818-A1 QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 ALDH1A1 661/4885HPGD 112/4885TSHR 3395/4885
US-20180072745-A1 IRE-1alpha INHIBITORS XBP1, ERN1, ATF4 ALDH1A1 2304/4885HPGD 1099/4885TSHR 2974/4885
US-20180118732-A1 QUINOLINONE FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH2 ALDH1A1 594/4885HPGD 122/4885TSHR 3244/4885
US-10807976-B2 Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors IDH1, IDH3A, IDH2 ALDH1A1 661/4885HPGD 112/4885TSHR 3395/4885
US-20120270877-A1 IRE-1alpha INHIBITORS XBP1, ERN1, ATF4 ALDH1A1 2304/4885HPGD 1099/4885TSHR 2974/4885
US-20170166576-A1 IRE-1alpha INHIBITORS XBP1, ERN1, ATF4 ALDH1A1 2304/4885HPGD 1099/4885TSHR 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.